Trial Profile

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

31 May 2020 Status changed from recruiting to completed, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
31 May 2020 Results assessing the role of stereotactic body radiosurgery (SBRT) along with full dose systemic chemotherapy in the treatment of unresectable stage 2 and stage 3 NSCLC, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
30 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com